Shannon Smiley is an Oncology physician. OpenAlex indexes 35 publications with 360 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3851 Piper Street
U340
Anchorage, AK 995084627
Telephone
907-562-0321Provider last certified this registry record 23 Jun 2021.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20255 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
- Janssen Biotech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
54.3%Platinum-based Drug22.9%Oxaliplatin100%Part B, office-administered≥16 patientsPD-1 inhibitor18.7%Pembrolizumab100%Part B, office-administered≥19 patients+ 8 more classes in this area
Musculoskeletal
25.1%RANK Ligand Inhibitor24.8%Denosumab100%Part B, office-administered≥30 patientsBisphosphonate0.2%Zoledronic acid100%Part B, office-administered≥24 patients+ 1 more class in this area
Metabolism & gastrointestinal
15.6%Other antiemetics14.3%Fosaprepitant100%Part B, office-administered≥22 patientsSerotonin-3 Receptor Antagonist1.2%Palonosetron hcl98%Ondansetron Hcl2%Part D + Part B<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation
2010 - Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation
2010 - Reversible cardiotoxicity with tyrosine kinase inhibitors.
PubMed
2010 - Atypical Presentation Of Vaginal GvHD With Abdominal Pain Crises
Biology of Blood and Marrow Transplantation
2010
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”